NEW YORK (GenomeWeb) – Publishing company Wiley said last week that it has acquired SimBioSys, a cheminformatics solutions developer, for an undisclosed sum.

Incorporated in 2006 as a spinout of the University of Leeds' Institute for Computer Applications in Molecular Sciences, SimBioSys describes itself as a biotechnology and chemistry software company focused on developing tools for structure-based, rational drug design. The firm's headquarters are in Toronto and it has distribution partners in Europe, Japan, China, and India.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Two recent papers published in Science and Nature Medicine describe work that may result in a universal vaccine for the flu.

In PNAS this week: The sea anemone is sequenced, a team describes a CRISPR/Cas9-based approach to label specific sites in the genome, and more. 

In a short video, CNN introduces viewers to a fecal transplant poop donor and explains how the treatments are made.

Researchers are testing the use of transgenically altered diamondback moths as an alternative to pesticides in controlling the bugs.